Drug
Nirogacestat clinical trials
Also written PF-03084014 and Ogsiveo.
- studies test it
- 25
- open now
- 5
- in phase 3
- 1
- first study started
- 2009
Keep track of what changes. Save the nirogacestat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
25 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 16
- Phase 3
- 1
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 9
Pfizer (6) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (5) · GlaxoSmithKline (3) · AIDS Malignancy Consortium (2) · Children's Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · Allogene Therapeutics (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Belantamab mafodotin (4) · Dexamethasone (4) · Lenalidomide (3) · Pomalidomide (2) · Famotidine (1) · Rabeprazole (1) · Elranatamab (1) · Docetaxel (1)
Studies
Open first, then newest update. How each study uses nirogacestat is read from its arms, and is right about nine times in ten.
Testing it · 25
- Nirogacestat in Patients With Kaposi SarcomaRecruitingPhase 2AIDS Malignancy ConsortiumNCT07539454Written as Nirogacestat
- Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)RecruitingPhase 4SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT07176689Written as Nirogacestat
- Study of Cryoablation and Nirogacestat for Desmoid TumorRecruitingPhase 2Nam BuiNCT05949099Written as Nirogacestat
- Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT05879146Written as Nirogacestat
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaRecruitingPhase 1/2Hellenic Society of HematologyNCT05573802Written as Nirogacestat
- A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by SurgeryActive, not recruitingPhase 2Children's Oncology GroupNCT04195399Written as Nirogacestat Hydrobromide
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Active, not recruitingPhase 2SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT07170644Written as Nirogacestat oral tablet
- Nirogacestat in Ovarian Granulosa Cell TumorsCompletedPhase 2SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT05348356Written as Nirogacestat
- Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)CompletedPhase 3SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT03785964Written as Nirogacestat oral tablet
- A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05556798Written as Nirogacestat
- Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingPhase 1/2GlaxoSmithKlineNCT07150104Written as Nirogacestat
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingPhase 1/2GlaxoSmithKlineNCT07150091Written as Nirogacestat
- Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)CompletedPhase 1Allogene TherapeuticsNCT04093596Written as Nirogacestat
- Evaluate the Effects of Famotidine or Rabeprazole on the PK of NirogacestatCompletedPhase 1SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT07171619Written as Nirogacestat
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMMActive, not recruitingPhase 1/2GlaxoSmithKlineNCT07084896Written as Nirogacestat
- MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaTerminatedPhase 2PfizerNCT05090566Written as Elranatamab + Nirogacestat
- Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive FibromatosisCompletedPhase 2National Cancer Institute (NCI)NCT01981551Written as PF-03084014
- A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple MyelomaTerminatedPhase 1Precision BioSciences, Inc.NCT04171843Written as Nirogacestat
- A Trial In Patients With Advanced Cancer And LeukemiaCompletedPhase 1PfizerNCT00878189Written as PF-03084014
- A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast CancerTerminatedPhase 1PfizerNCT01876251Written as PF-03084014
See all 25 studies that test nirogacestat →
Given in every arm · 3 — nirogacestat is usual care beside what is tested
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Nirogacestat
- A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04722146Written as Nirogacestat
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingPhase 1/2GlaxoSmithKlineNCT04126200Written as Nirogacestat
As the comparator · 1 — what is tested is compared with nirogacestat
Codes
What other systems call nirogacestat · ClinicalTrials.gg INT005668
- MeSH (NLM) C550722nirogacestatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) QZ62892OFJNIROGACESTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27088329nirogacestatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82383NirogacestatOne source FDA
- DrugBank DB12005One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C550722 | nirogacestat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QZ62892OFJ | NIROGACESTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088329 | nirogacestat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82383 | Nirogacestat | One source FDA |
| DrugBank | DB12005 | — | One source Wikidata |
Also registered as nirogacestat hydrobromide (UNII 9T1XY6L45Y).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.